EUVIMEDEUVIMED entdecken
Crossref

A PROMISING LIPOSOMAL VACCINE CANDIDATE AGAINST EPSTEIN-BARR VIRUS: AN IN VITRO EVALUATION

Atieh Rezvankhah, Jülide Secerli, Merve Güdül Bacanlı, Gamze Varan

Ankara Universitesi Eczacilik Fakultesi Dergisi · 19.05.2026 · 50 (2) · 322-337

DOI: 10.33483/jfpau.1818424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ankara Universitesi Eczacilik Fakultesi Dergisi, online erschienen am 19.05.2026. Verfasst von Atieh Rezvankhah und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Hacettepe University Scientific Research Projects Coordination Unit.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective: In this study, we developed PEGylated-liposomes encapsulating full-length gp350 with MPLA adjuvant, systematically modulating DOPC- versus DOPE-based bilayers to reveal how lipid composition influences physicochemical properties, cytotoxicity, ROS generation, genotoxicity, stability, and cytokine induction, establishing a novel nano-encapsulation platform that informs the rational design of next-generation EBV subunit vaccines capable of eliciting coordinated innate and early adaptive immune responses.Material and Method: PEGylated-liposomes were prepared using DOPC- and DOPE-based bilayers to compare their physicochemical characteristics. Particle size, PDI, and zeta potential were analyzed by DLS. Encapsulation efficiency, stability at 4°C for 30 days, and antigen release kinetics at 37°C were determined. Cytotoxicity (MTT, LDH assays), oxidative and genotoxic stress (ROS, comet assays), and cytokine responses (TNF-α, IL-6, IL-10) in THP-1–derived macrophages were evaluated to assess safety and immunostimulatory capacity.Result and Discussion: Both formulations produced nanoparticles smaller than 200 nm with high encapsulation efficiency (>90%) and maintained stability for at least 30 days. DOPC-based liposomes exhibited a sustained antigen release (25% at 24 h), whereas DOPE-based liposomes showed a rapid burst release (60% within 6 h). Cytotoxicity, ROS, and comet assays indicated superior biocompatibility of the DOPC-based formulation. Immunological analysis revealed that the DOPC formulation induced a balanced cytokine profile with robust TNF-α and IL-6 expression, moderate IL-10 secretion, and a Th1-skewed response, while the DOPE-based formulation displayed an IL-6–dominant pattern. Collectively, these results identify DOPC-based PEGylated-liposomes as a safe, stable, and immunostimulatory platform for gp350 delivery, highlighting their promise as a next-generation EBV vaccine candidate.

Förderung

  • Hacettepe University Scientific Research Projects Coordination Unit

Zitieren

APA

Rezvankhah, A., Secerli, J., Bacanlı, M. G., & Varan, G. (2026). A PROMISING LIPOSOMAL VACCINE CANDIDATE AGAINST EPSTEIN-BARR VIRUS: AN IN VITRO EVALUATION. Ankara Universitesi Eczacilik Fakultesi Dergisi, 50(2), 322-337. https://doi.org/10.33483/jfpau.1818424

Vancouver

Rezvankhah A, Secerli J, Bacanlı MG, Varan G. A PROMISING LIPOSOMAL VACCINE CANDIDATE AGAINST EPSTEIN-BARR VIRUS: AN IN VITRO EVALUATION. Ankara Universitesi Eczacilik Fakultesi Dergisi. 2026;50(2):322-337. doi:10.33483/jfpau.1818424

BibTeX
@article{Rezvankhah2026,
  author = {Rezvankhah, Atieh and Secerli, Jülide and Bacanlı, Merve Güdül and Varan, Gamze},
  title = {A PROMISING LIPOSOMAL VACCINE CANDIDATE AGAINST EPSTEIN-BARR VIRUS: AN IN VITRO EVALUATION},
  journal = {Ankara Universitesi Eczacilik Fakultesi Dergisi},
  year = {2026},
  volume = {50},
  number = {2},
  pages = {322--337},
  doi = {10.33483/jfpau.1818424}
}
Kostenlos starten →